Abstract
Objectives
To investigate the clinical and image characteristics of primary systemic vasculitis-associated optic neuritis patients.
Methods
This is a retrospective study. The patients clinically diagnosed with primary system vasculitis-induced optic neuritis were recruited from March 2013 to December 2023. All cases received orbital magnetic resonance imaging scans were analyzed. The ocular findings, systemic manifestations, laboratory data and prognosis were reviewed retrospectively. In addition, the related literature was reviewed.
Results
Fourteen patients (21 eyes), including 10 men and 4 women, were enrolled in this study. The ages ranged from 30 to 86 years in this cohort. Orbits MRI detects the enlargement and/or enhancement of the optic nerve. Cases 1–5 reported a confirmed diagnosis of Takayasu’s arteritis, and cases 6–8 had giant cell arteritis. Cases 9–13 were antineutrophil cytoplasmic antibody-associated vasculitis. Case 14 was Cogan’s syndrome. Mult organs and tissues, such as the kidneys, heart, paranasal sinuses, meninges, and respiratory system, were involved. In all of the 14 involved patients, the disease onset was either during the fall or winter season. There were no or only slight improvements in visual activity after conventional therapies.
Conclusions
The autoantibodies’ attack on the optic nerve, ischemic damage, or destruction of the blood–brain barrier may be the potential pathogenesis of vasculitis-associated optic neuritis. Even with prompt and aggressive clinical interventions, the prognosis remains unsatisfactory.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Primary systemic vasculitis (PSV) involves a heterogeneous group of uncommon pathologies characterized by vesicular inflammation and necrosis of the arteries, veins, and capillary beds in specific tissues or organs. The optic nerve is affected in rare cases but with irreversible visual damage. The most used nomenclature of PSV is according to the size of the affected vessel [1]. Large vessel vasculitis (LVV) presents a necrotizing inflammation involving the large arteries, such as giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Small vessel vasculitis (SVV) is characterized by a small-vessel necrotizing vasculitis or granuloma formation, which includes antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and immune complex deposition-induced vasculitis. Some patients may have all sizes of vasculitides involved, such as Cogan’s syndrome (CS).
Ocular manifestations are usually detected in 34.1% of granulomatosis with polyangiitis (GPA) patients, 8.9% of microscopic polyangiitis (MPA) patients [2], 10–20% of GCA patients, and < 10% of TAK patients [3]. Notably, an initial diagnosis of ocular vasculitis can be an indicator of upcoming life-threatening PSV conditions. Systemic and local vasculitis occur concurrently or at a later stage of PSV, involving bilaterally or unilaterally eyes [2]. Conjunctivitis, episcleritis, and keratitis are the most common anterior segment manifestations. Orbit involvement includes orbital pseudotumor, nasolacrimal duct obstruction, and proptosis. Vascular complications present as retinal/choroidal artery occlusion [4].
PSV-related optic neuropathies are usually developed due to compression by orbital mass or contiguous spread of inflammation from meninges/orbit/sinuses, or GCA induced- arteritic anterior ischemic optic neuropathy (AAION). Optic neuritis (ON) is exceptionally rare in PSV patients. Both ophthalmologists and rheumatologists paid little attention to PSV-linked optic neuritis (PSV-ON), leading to delays in diagnosis and vision damage. Herein, we present 14 cases (21 eyes) of PSV-ON and review the relevant studies.
Methods
We retrospectively collected the in-house developed electronic medical records (EMRs) of PSV-ON patients from August 2013 to August 2023 in Beijing Friendship Hospital affiliated with Capital Medical University. The EMRs data contains the patient’s massages, diagnoses, laboratory findings, radiological records, interventions et al. All enrolled cases received ophthalmic assessments before and after the treatment. Visual ability was assessed by the Logarithmic standard visual acuity chart. The orbital and brain magnetic resonance imaging (MRI) examinations were performed before treatment, using a 3.0-T scanner, including T1, T2, and T1 post-gadolinium MRI. All data were collected and analyzed by experienced neuro-ophthalmologists and neuro-radiologists. The diagnosis of PSV was made based on the 2022 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria [5,6,7,8]. All diagnoses were consulted with experienced rheumatologists and nuclear medicine specialists. The diagnosis of PSV-ON was confirmed by evaluating the visual function impairments and characteristic changes of the optic nerve on MRI, like optic nerve hyperintensities in T2-weighted images (T2WI), abnormal enlargement and/or enhancement of optic nerve parenchyma/sheath in T1-weighted postcontrast MRI, and without orbital apex enhancement or inflamed masses compressing the optic nerves. Optic neuritis associated with other neurological diseases was excluded. Such as multiple sclerosis-associated ON and neuromyelitis optica spectrum disorder-associated ON. Optic perineuritis (OPN) and cases without sufficient clinical information were excluded.
This study was approved by the internal ethics committee of the hospital and conducted following the Declaration of Helsinki. All patients provided consent for further analysis and publishing of their medical findings to help the scientific community and doctors make treatment strategies.
Results
Fourteen cases (21 eyes), including 10 men and 4 women, were enrolled in this study. The ages ranged from 30 to 86 years in this cohort. Cases 1–5 reported a confirmed diagnosis of TAK, and cases 6–8 had GCA. Cases 9–13 were all diagnosed with AAV with multiple organ involvement. Cases 9 and 10 were identified as GPA and positive for cANCA, while cases 10–13 were identified as pANCA-positive MPA for further investigation. Case 14 was diagnosed with CS.
Optic neuritis in 14 patients, 7 cases involved bilateral eyes. Fourteen eyes presented disc edema, and 2 eyes with optic atrophy in 21 affected eyes. Twelve patients manifested retinal/choroidal vasculitis as well as optic neuritis. Such as retinal cotton wool spots, retinal arterial obstruction, vascular wall staining and fluorescein leakage in fluorescein angiography (FA).
The extra-ocular manifestations of the PSV were summarized. The kidneys were involved in six cases (cases 1, 10–14). Case 1 with TAK explores the renal dysfunction induced by renal arteritis. Cases 10–13 with ANCA-arteritis manifest interstitial renal diseases. Four cases (cases 4, 9, 10, 13) had sinusitis and/or mastoiditis. Cases 9 and 11 had hypertrophic pachymeningitis. Myocardial damage occurred in cases 1,3 and 13. Respiratory tract involved in cases 1,10–13. Oculomotor neuritis and ON coexisted in case 3. Acoustic neuritis and ON coexisted in case 14.
The extra-ocular image findings of the PSV are present in Figs. 1, 2, 3 and 4. 18F-FDG-PET in Fig. 1 shows high accumulations of radioisotopes in multivessels of TAK patients. Figure 3B shows bilateral ethmoid sinus, maxillary sinus, and dura mater were involved in a 49-year-old man with GPA (case 9). Figure 3D shows discrete T2-weight hyperintense signals at the left maxillary sinus in a 71-year-old man with a GPA (case 10). Figure 3F is a 58-year-old man with MPA (case 11). MRI shows thickened and enhanced signals at the dura mater. Figure 4 is a 30-year-old woman with Cogan’s Syndrome. Her bilateral threshold of audibility shows moderate to severe sensorineural hearing loss. High accumulation in the renal cortex was detected in 18F-FDG-PET.
In all of these cases, the disease onset was either during the fall or winter season. The demographics and clinical data of enrolled cases are summarized in Table 1.
Literature review
Twenty-three patients with PSV-ON have been reported in the literature [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26]. The literature review was conducted as follows: (1) Patients diagnosed with optic neuritis. (2) The optic neuropathy with characteristic changes on MRI. MRI changes include optic nerve hyperintensities in T2WI, optic nerve parenchyma/sheath enlargement and enhancement in T1WI postcontrast MRI. (3) OPN is excluded from this review. The clinical characteristics are summarized in Table 2. ON has been frequently diagnosed in AAV patients (15 cases), followed by GCA patients (6 cases). Two atypical CS patients presented ON.
Discussion
The ON is an exceedingly rare presentation of PSV. Even with prompt aggressive therapies, the prognosis remains poor. In all the 14 involved patients, there were no or only slight improvements in visual activity after treatments. Two of them are even worse during combination therapies.
The exact prevalence, prognosis, and pathophysiology of PSV-ON are unclear. The incidence rate of PSV is 40–54 per million cases. However, this counting may vary due to age, genetics, geographical location, and climatic changes. Clinical manifestations are variable in patients with different sizes of vascular obstruction. GCA and TAK are necrotizing vasculitides of unclear etiology, especially for medium or large vessels. They preferred to affect women. Epidemiologically, GCA affects older people, with the incidence peaking in the seventh decade. In a cohort of age over 90 years, the risk of GCA is reportedly 20 times. TAK is the most typical syndrome among Asian individuals, and 80–90% of cases are found in the 1st–3rd decades of life [27]. Several types of SVV can be associated with the serum positivity of ANCA. AAV targets capillaries, venules, and arterioles. But sometimes, middle-sized arteries can also be affected. AAV can develop at any age. Generally, AAV presents 3 major phenotypes: GPA, MPA and eosinophilic granulomatosis with polyangiitis (EGPA) [28]. ANCAs exhibit 2 distinct intracellular distribution patterns-diffuse cytoplasmic ANCAs (cANCA) directing against proteinase 3 (PR3) and perinuclear ANCAs (pANCA) against myeloperoxidase (MPO) [29]. cANCA (PR3-ANCA) is associated with GPA, while pANCA (MPO-ANCA) has been linked to MPA and EGPA. CS is a rare autoimmune multisystem inflammatory vasculitis that involves blood vessels of all sizes. CS is typically detected in young adults of any gender in their 2nd or 3rd decade of life, occasionally in middle age [30]. Although different vasculitis predilects for sizes of vessels, vascular involvement can be widespread to any size. Such associations are not necessarily exclusive and occur interchangeably. Interestingly, vasculitis peaks in particular seasons. All of our cases reported the onset during the fall and winter.
The systemic necrotizing vasculitis leads to vascular occlusion, consequently leading to poor end-organ perfusion. The brain, lungs, kidneys, and heart dysfunctions are the most common systemic presentations associated with necrotizing LVV pathology. In our research, the TAK patient (case 1) had large vessel vasculitis. He accompanied multiple organ impairments, including multiple lacunar infarcts, atypical pathogenic pneumonia, reduced left-ventricular ejection fraction, and renal dysfunction. Moreover, small vessels and retinal/choroid arteria can also impaired [31]. The interstitial or connective tissue lesion is a well-known presentation of ANCA-associated vasculitis. In this study, a higher incidence of interstitial renal/lung disease is noted among ANCA-arteritis patients (cases 10–13). GPA is a kind of ANCA-arteritis with dual-form. It presents necrotizing vasculitis as well as extravascular granulomatous inflammation. In a previous study, the ear, nose, and throat manifestations are observed in 90% of GPA patients [16]. In our study, cases 4, 9, 10 and 13 presented sinusitis and mastoiditis, representing pathologic changes of granulomatous vasculitis. MPA, another kind of ANCA-arteritis, is a systemic necrotizing vasculitis without granulomatous inflammation that distinguishes MPA from GPA. Additionally, hypertrophic pachymeningitis was present as the main feature of GPA (case 9) and MPA (case 11) in our study, as previously report [32]. Approximately 70% of CS patients have underlying vasculitis-induced systemic diseases [33] not only localized on the oculo-audio vestibular. Such as interstitial renal diseases in case 14.
The ocular manifestations of PSV have been widely reported. The tortuosity and dilatation of the retinal vessels or occlusion of the retinal artery are characteristic of retinal vasculitis. In most PSV-ON cases, localized occlusions of the retinal artery were observed at the acute phase, which eventually converted to atrophy of a sector at the later stage. GCA-associated small artery-end inflammation commonly leads to AAION [34]. TAK-associated hypertension or carotid occlusion frequently induces ocular ischemic syndromes and retinopathies. It seems ocular involvement is not caused by vasculitis directly. The anterior segment manifestations are more prominently noticed in AAV patients [2, 35, 36]. The orbital manifestations occurred in GPA specificity. A retrospective study has reported that 45% of GPA patients are accompanied by orbital infiltration due to contiguous granulomatous spreading from the paranasal sinus [37]. Typical CS is characterized by recurrent episodes of deafness and visual loss due to cochleovestibular dysfunction and interstitial keratitis, respectively. Atypical CS patients may present uveitis (37%), scleritis (23%), conjunctivitis (10%), cataract, and other ocular manifestations [30].
PSV-ON is a fatal disorder as it can lead to acute visual or central visual field loss. PSV is a critical pathogenesis for the onset of ON, although it is rarely reported. Diagnosis of PSV-ON may sometimes be delayed or misinterpreted in complex clinical manifestations of vasculitis [12, 23]. Optic nerve involvement is reportedly 0.8% in GPA and 8.0% among MPA patients [2]. Several kinds of literature have mentioned optic nerve sheath enhancement in patients with GCA [9, 10, 38, 39]. Most PSV-ON patients were positive for pANCA. Unfortunately, relevant studies have reported mixed and sometimes contradictory findings on ON.
The underlying hypothesis for the mechanism of action might be as follows. First, the penetrating pial vessels provide nutrition to the nerve parenchyma and sheath [39]. Focal vascular necrosis and hypercoagulability-induced thrombosis may cause vasculitic infarction and optic nerve ischemic damage. The second reason could be the disruption of the blood–brain barrier (BBB) permeability. Sidney et al. [40] have reported that patients with bilateral optic nerve sheath enhancement may not develop optic neuropathies. The intrinsic arteritis may not develop related optic parenchyma neuropathy. But in unrecognized or untreated vasculitis conditions, ON may onset. Third, PSV-induced autoantibodies may cross-react with neuronal cells. It is believed that in PSV-ON patients, the optic nerve is attacked by autoantibodies rather than vasculitis. The previous report confirmed the common antigens present in the inner ear and cornea in the CS patient.
There are only case series reports helping guide PSV-ON management. A prioritised treatment option is high-dose steroids at the onset. Most of these patients ultimately require a more complex regimen to induce remission and prevent PSV and ON recurrences, like a combination of biological drugs, steroids, and cyclophosphamide. The newer biological drugs, especially antagonists of interleukin-6 (IL-6) and tumor necrosis factor (TNF) might be beneficial in complicated PSV-ON cases [41]. Even with prompt therapy, GPA-associated ON often has an unfavourable prognosis. The permanent, complete or partial vision loss has been reported to be 15–20% in GCA [31]. It is hypothesised that distinctive pathology leads to divergent responses to steroids. Only half of TAK patients respond to steroids. The lack of prompt treatment may be an additional agent. Atypical CS tends to be more aggressive and has a worse prognosis. Manteiro et al. [18] have suggested that occlusive vasculitis-associated ON can be treated effectively via rapid diagnosis and aggressive anti-inflammatory therapies. However, the early-stage diagnosis of ON may sometimes be difficult due to atypical or incomplete clinical manifestations. Accordingly, optic nerve irreversible ischemic or autoimmune damage is present and without remedy methods.
Conclusion
PSV-ON is a rare but sight-threatening disease. The autoantibodies’ attack on the optic nerve, ischemic damage, or destruction of the BBB may be potential pathogenesis. Even with prompt and aggressive clinical interventions, the prognosis remains unsatisfactory. An early diagnosis is crucial for preventing irreversible injuries to the optic nerve.
Limitation
Our study utilized a retrospective design and was limited to a single center. There may have been some selection bias. Stringent inclusion criteria limited our sample size to 14 patients, which may have underpowered some aspects of the study. Neuromyelitis optica spectrum disorder (NMOSD) and PSV are all mult-organs involved syndromes. Optic neuritis and NMOSD-ON have overlapping clinical profiles. NMOSD-ON is not enrolled in this research. Furthermore, since all patients were identified within inpatients, there was likely selection bias toward identification.
Availability of data and material
All of the data in this study were in the article. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
References
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11
Rothschild PR, Pagnoux C, Seror R, Brézin AP, Delair E, Guillevin L (2013) Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum 42(5):507–514
Dhanani U, Zhao MY, Charoenkijkajorn C, Pakravan M, Mortensen PW, Lee AG (2022) Large-vessel vasculitis in ophthalmology: giant cell arteritis and Takayasu arteritis. Asia-Pacific J Ophthalmol (Philadelphia, Pa.) 11(2):177–183
Kubal AA, Perez VL (2010) Ocular manifestations of ANCA-associated vasculitis. Rheum Dis Clin North Am 36(3):573–586
Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA (2022) 2022 American college of rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 81(12):1647–1653
Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA (2022) 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 81(3):315–320
Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Danda D, Luqmani RA, Watts RA, Merkel PA (2022) 2022 American college of rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis 81(12):1654–1660
Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, Judge A, Hutchings A, Merkel PA, Luqmani RA, Watts RA (2022) 2022 American college of Rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 81(3):321–326
Lee AG, Eggenberger ER, Kaufman DI, Manrique C (1999) Optic nerve enhancement on magnetic resonance imaging in arteritic ischemic optic neuropathy. J Neuro-Ophthalmol Official J North Am Neuro-Ophthalmol Soc 19(4):235–237
D’Souza NM, Morgan ML, Almarzouqi SJ, Lee AG (2016) Magnetic resonance imaging findings in giant cell arteritis. Eye (Lond) 30(5):758–762
Garcia-Porrua C, Santamarina R, Armesto V, Gonzalez-Gay MA (2005) Magnetic resonance imaging in optic neuritis due to giant cell arteritis. Arthritis Rheum 53(2):313–314
Salvi F, Mascalchi M, Pasini E, Bartolomei I, Fini N, Marliani F, Malatesta R, Michelucci R (2010) p-ANCA pachymeningitis presenting with isolated “optic neuropathy.” Neurol Sci Official J Italian Neurol Soc Italian Soc Clin Neurophysiol 31(5):639–641
Sasaki R, Taniguchi A, Narita Y, Naito Y, Kuzuhara S (1995) A case of optic neuropathy, recurrent transverse myelopathy and hypertrophic pachymeningitis associated with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA). Rinsho shinkeigaku = Clin Neurol 35(5):513–515
Harada T, Ohashi T, Harada C, Yoshida K, Maguchi S, Moriwaka F, Matsuda H (1997) A case of bilateral optic neuropathy and recurrent transverse myelopathy associated with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA). J Neuro-Ophthalmol Official J North Am Neuro-Ophthalmol Soc 17(4):254–256
Miyanaga M, Takase H, Ohno-Matsui K (2021) Anti-neutrophil cytoplasmic antibody-associated ocular manifestations in japan: a review of 18 Patients. Ocul Immunol Inflamm 29(5):991–996
Suga K, Nomoto Y, Sudo A, Isogai J, Suzuki Y, Kagami SI (2020) Granulomatosis with polyangiitis complicated with refractory optic neuritis and maxillary osteomyelitis. Mod Rheumatol Case Rep 4(1):79–83
Huchzermeyer C, Mardin C, Holbach L, Zwerina J, Schett G, Rech J (2013) Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener’s granulomatosis. Clin Rheumatol 32(Suppl 1):S97-101
Monteiro ML, Borges WI, de Val Ferreira C, Ramos LTL, Leite CC (2005) Bilateral optic neuritis in Wegener granulomatosis. J Neuro-Ophthalmol Official J North Am Neuro-Ophthalmol Soc 25(1):25–28
Fauci AS, Wolff SM (1973) Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine 52(6):535–561
Cutler WM, Blatt IM (1956) The ocular manifestations of lethal midline granuloma (Wegener’s granulomatosis). Am J Ophthalmol 42(1):21–35
Moubayed SP, Black DO (2009) Optic neuritis as an initial presentation of Wegener’s granulomatosis. Canadian J Ophthalmol 44(6):e59
Belden CJ, Hamed LM, Mancuso AA (1993) Bilateral isolated retrobulbar optic neuropathy in limited Wegener’s granulomatosis. J Clin Neuroophthalmol 13(2):119–123
Altaie R, Ditizio F, Fahy GT (2005) Microscopic polyangitis presenting with sub-acute reversible optic neuropathy. Eye (Lond) 19(3):363–365
Oshida EM, Suzuki Y, Chikuda T, Sakurai M (2004) Retro bulbar optic neuritis in a case of nephritis related to anti-neutrophil cytoplasmic antibody (ANCA) (in Japanese, with English abstract). Rinsho Ganka (Jpn J Clin Ophthalmol) 58:1499–1503
Yamamoto K, Takase Y, Nogaki H, Fukusako T, Morimatus M (1990) A case of Cogan’s syndrome associated with multiple cranial neuropathy. Rinsho shinkeigaku = Clin Neurol 30(6):639–642
Bicknell JM, Holland JV (1978) Neurologic manifestations of Cogan syndrome. Neurology 28(3):278–281
Papaliodis GN (2017) Ophthalmologic manifestations of systemic vasculitis. Curr Opin Ophthalmol 28(6):613–616
McKinney EF, Willcocks LC, Broecker V, Smith KG (2014) The immunopathology of ANCA-associated vasculitis. Seminars Immunopathol 36(4):461–478
Mercuzot C, Letertre S, Daien CI, Zerkowski L, Guilpain P, Terrier B, Fesler P, Roubille C (2021) Comorbidities and health-related quality of life in patients with antineutrophil cytoplasmic antibody (anca)—associated vasculitis. Autoimmun Rev 20(1):102708
Gluth MB, Baratz KH, Matteson EL, Driscoll CL (2006) Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 81(4):483–488
Singh AG, Kermani TA, Crowson CS, Weyand CM, Matteson EL, Warrington KJ (2015) Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol 42(2):309–315
Gupta V, Sharma AK, Sureka RK, Bhuyan SK, Singh PK (2013) Chronic meningitis with multiple cranial neuropathies: a rare initial presentation of Wegener’s granulomatosis. Ann Indian Acad Neurol 16(3):411–413
Maikap D, Pradhan A, Padhan P (2022) A rare case of atypical Cogan’s syndrome presenting as encephalitis. Mod Rheumatol Case Rep 6(2):305–308
Hayreh SS, Podhajsky PA, Zimmerman B (1998) Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125(4):509–520
Gu J, Zhou S, Ding R, Aizezi W, Jiang A, Chen J (2013) Necrotizing scleritis and peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Ophthalmol Therapy 2(2):99–111
Fujita Y, Fukui S, Endo Y, Tsuji S, Takatani A, Shimizu T, Umeda M, Nishino A, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki R, Uematsu M, Ishida K, Abe K, Kawakami A (2018) Peripheral ulcerative keratitis associated with granulomatosis with polyangiitis emerging despite cyclophosphamide, successfully treated with rituximab. Internal Med (Tokyo, Japan) 57(12):1783–1788
Haynes BF, Fishman ML, Fauci AS, Wolff SM (1977) The ocular manifestations of Wegener’s granulomatosis fifteen years experience and review of the literature. Am J Med 63(1):131–141
AlShaker S, Shemesh AA, Margolin E (2018) Enhancement of optic nerve sheath in AAION: a case of visual recovery in fulminant GCA. Canadian J Ophthalmol 53(6):e236–e239
Sommer NN, Treitl KM, Coppenrath E, Kooijman H, Dechant C, Czihal M, Kolben TM, Beyer SE, Sommer WH, Saam T (2018) Three-dimensional high-resolution black-blood magnetic resonance imaging for detection of arteritic anterior ischemic optic neuropathy in patients with giant cell arteritis. Invest Radiol 53(11):698–704
Gospe SM 3rd, Amrhein TJ, Malinzak MD, Bhatti MT, Mettu P, El-Dairi MA (2021) Magnetic resonance imaging abnormalities of the optic nerve sheath and intracranial internal carotid artery in giant cell arteritis. J f Neuro-ophthalmol Official J North Am Neuro-Ophthalmol Soc 41(1):54–59
Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44(12):2933–2935
Acknowledgements
The authors thank all the staff of Beijing Friendship Hospital for their contributions to this work. Thank MedEditing (www.medediting.com) for the English language editing service.
Funding
This work is supported by “Capital’s Funds for Health Improvement and Research (CFH) (Grant No.2022–2-20211)” This funding will not lead to any conflict of interest regarding the publication.
Author information
Authors and Affiliations
Contributions
SM.T contributed to the acquisition, analysis and interpretation of data as well as drafting the manuscript and revising it critically. R.L and Y.W reviewed the images. H.Z and YL.H contributed to data curation and analysis. YL.H and HY.L were involved in the conception and design of the study. All authors contributed to the article and approved the submitted version.All authors reviewed the manuscript. All authors have given final approval for the version to be published. The written consent to publish this information was obtained from study participants.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest regarding the publication of this article.
Ethics approval and consent to participate
This study was approved by the BFH Ethics Committee and was conducted following the latest iteration of the Declaration of Helsinki (version:2020-P2-314–01). Participants were given written informed consent (version V1.0 /2020–01-01) before inclusion in the study. All blood samples were collected as part of routine treatment for this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tang, S., Zhou, H., Li, R. et al. The primary systemic vasculitis associated optic neuritis: a retrospective analysis in a single center over 10 years. Int Ophthalmol 44, 387 (2024). https://doi.org/10.1007/s10792-024-03307-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10792-024-03307-2